Anamorelin
Aliases: Adlumiz · ONO-7643
Last verified: 2026-09-23
The short version
An oral ghrelin mimetic — approved in Japan (2021) for cancer cachexia: increases appetite and lean mass.
Identity & type
- Molecular type
- mali molekul
- Origin
- An oral ghrelin mimetic — approved in Japan (2021) for cancer cachexia: increases appetite and lean mass.
Mechanism of action
GHS-R1a agonism → GH + appetite.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 100 mg/day orally (approved).
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100 mg/day orally (approved). In cachexia (Japan): appetite and body-mass gains; the community outside the indication rarely uses it due to price/availability.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
In cachexia (Japan): appetite and body-mass gains; the community outside the indication rarely uses it due to price/availability.
Protocol — official vs community
Official / label
Approved in Japan (Adlumiz) for cancer cachexia: 100 mg oral daily.
- 01Flat 100 mg daily dose
Duration: Continuous while indicated.
The only approved oral ghrelin agonist — exists precisely because cachexia patients need appetite, not restraint.
Community (anecdotal)
Gray-market use mirrors the label (100 mg oral daily).
- Cycle:
- Continuous anecdotally.
- Break:
- None documented.
Buying a cachexia drug for gym appetite is a category error with real metabolic costs.
Human evidence
ROMANA trials (NSCLC cachexia): significant lean-mass gains.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Hyperglycemia, nausea; contraindicated in GI obstruction.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials